Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:ELEVNASDAQ:FATENASDAQ:IPSCNYSE:JNJNASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$1.61-2.7%$1.43$0.91▼$6.69$134.36M2.162.58 million shs778,601 shsELEVElevation Oncology$0.35-6.6%$0.38$0.22▼$4.48$20.55M1.651.36 million shs306,730 shsFATEFate Therapeutics$1.24-3.5%$1.01$0.66▼$5.92$140.39M2.412.29 million shs661,641 shsIPSCCentury Therapeutics$0.55+1.9%$0.54$0.34▼$3.70$47.56M1.83434,538 shs737,943 shsJNJJohnson & Johnson$154.69-1.0%$159.24$140.68▼$169.99$371.84B0.497.90 million shs3.53 million shsYMABY-mAbs Therapeutics$4.10-3.5%$4.76$3.84▼$17.78$184.49M0.71326,451 shs119,698 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+6.45%+5.77%+42.24%+20.44%-68.33%ELEVElevation Oncology+7.27%-1.90%+43.42%-44.25%-89.53%FATEFate Therapeutics+9.40%-3.76%+62.00%-6.57%-67.59%IPSCCentury Therapeutics+7.44%+0.30%+13.78%-36.28%-81.39%JNJJohnson & Johnson+0.27%+0.63%-5.77%+2.32%+8.10%YMABY-mAbs Therapeutics+1.19%+3.16%-4.06%-31.34%-72.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.1671 of 5 stars3.23.00.04.22.61.71.3ELEVElevation Oncology2.4021 of 5 stars4.21.00.00.02.11.70.6FATEFate Therapeutics3.7548 of 5 stars3.12.00.04.72.11.70.6IPSCCentury Therapeutics1.9875 of 5 stars3.51.00.00.02.41.70.6JNJJohnson & Johnson4.6504 of 5 stars3.33.04.23.92.72.50.6YMABY-mAbs Therapeutics3.8197 of 5 stars4.43.00.00.02.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.31Hold$6.54307.38% UpsideELEVElevation Oncology 2.30Hold$3.39875.71% UpsideFATEFate Therapeutics 2.22Hold$5.43339.56% UpsideIPSCCentury Therapeutics 3.00Buy$4.40697.10% UpsideJNJJohnson & Johnson 2.63Moderate Buy$171.8211.08% UpsideYMABY-mAbs Therapeutics 2.82Moderate Buy$17.40324.39% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.004/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/22/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.004/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/16/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/16/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.004/14/2025JNJJohnson & JohnsonRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.004/10/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M4.16N/AN/A$4.27 per share0.38ELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AFATEFate Therapeutics$13.63M10.38N/AN/A$3.74 per share0.33IPSCCentury Therapeutics$6.59M7.22N/AN/A$3.06 per share0.18JNJJohnson & Johnson$89.33B4.17$12.71 per share12.17$29.69 per share5.21YMABY-mAbs Therapeutics$87.69M2.11N/AN/A$2.32 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$2.88N/AN/AN/A-340.96%-80.13%-50.99%5/6/2025 (Estimated)ELEVElevation Oncology-$45.70M-$0.81N/AN/AN/AN/A-59.73%-40.05%5/1/2025 (Estimated)FATEFate Therapeutics-$160.93M-$1.64N/AN/AN/A-1,325.43%-45.88%-33.95%5/8/2025 (Estimated)IPSCCentury Therapeutics-$136.67M-$1.63N/AN/AN/A-4,837.73%-61.66%-31.78%5/8/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9923.2413.972.5618.20%34.24%13.63%7/16/2025 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.67N/AN/AN/A-28.22%-24.61%-18.49%5/6/2025 (Estimated)Latest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025EDITEditas Medicine-$0.52N/AN/AN/A$0.79 millionN/A5/8/2025Q1 2025FATEFate Therapeutics-$0.39N/AN/AN/A$1.18 millionN/A5/8/2025Q1 2025IPSCCentury Therapeutics-$0.31N/AN/AN/AN/AN/A5/6/2025Q1 2025YMABY-mAbs Therapeutics-$0.21N/AN/AN/A$19.97 millionN/A5/1/2025Q1 2025ELEVElevation Oncology-$0.20N/AN/AN/AN/AN/A4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion3/19/2025Q4 2024IPSCCentury Therapeutics-$0.45-$0.43+$0.02-$0.43$0.67 million$4.18 million3/6/2025Q4 2024ELEVElevation Oncology-$0.22-$0.18+$0.04-$0.18N/AN/A3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 million3/5/2025Q4 2024FATEFate Therapeutics-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 million3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.203.36%+5.43%57.84%64 YearsYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ALatest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.753.75ELEVElevation Oncology0.4517.7717.77FATEFate TherapeuticsN/A8.298.29IPSCCentury TherapeuticsN/A10.3910.39JNJJohnson & Johnson0.431.110.86YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%ELEVElevation Oncology83.70%FATEFate Therapeutics97.54%IPSCCentury Therapeutics50.20%JNJJohnson & Johnson69.55%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%ELEVElevation Oncology8.10%FATEFate Therapeutics5.00%IPSCCentury Therapeutics6.80%JNJJohnson & Johnson0.16%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableELEVElevation Oncology4059.22 million54.33 millionOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableIPSCCentury Therapeutics17086.16 million79.25 millionOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableYMABY-mAbs Therapeutics15045.22 million34.71 millionOptionableYMAB, IPSC, EDIT, FATE, JNJ, and ELEV HeadlinesRecent News About These CompaniesY-mAbs Therapeutics (YMAB) Projected to Post Earnings on TuesdayMay 1 at 9:32 AM | marketbeat.comJPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 30 at 3:04 AM | marketbeat.comEarnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to DeclineApril 29 at 11:05 AM | zacks.comBoothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 29 at 6:24 AM | marketbeat.comY-mAbs Therapeutics announces presentation of PK data of CD38-SADAApril 28 at 12:06 AM | markets.businessinsider.comY-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measuresApril 27, 2025 | finance.yahoo.comY-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual MeetingApril 27, 2025 | globenewswire.comBrookline Capital Management Weighs in on YMAB Q1 EarningsApril 27, 2025 | marketbeat.comY-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platformApril 26, 2025 | markets.businessinsider.comYMAB Q1 EPS Estimate Reduced by Brookline Capital ManagementApril 26, 2025 | americanbankingnews.comY-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of AmericaApril 24, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Underperform" at Bank of AmericaApril 24, 2025 | americanbankingnews.comY-mAbs Therapeutics downgraded to Underperform from Neutral at BofAApril 23, 2025 | markets.businessinsider.comY-mAbs downgraded to Underperform at BofA on tough near-term setupApril 23, 2025 | markets.businessinsider.comY-mAbs drops as Bank of America downgrades on headwinds to DanyelzaApril 23, 2025 | msn.comWhy Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 7.47%April 23, 2025 | aaii.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.April 16, 2025 | cnn.comY-mAbs Therapeutics: A Yawn From The Market Means OpportunityApril 11, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.By Leo Miller | April 28, 2025View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? By Chris Markoch | April 16, 2025View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? YMAB, IPSC, EDIT, FATE, JNJ, and ELEV Company DescriptionsEditas Medicine NASDAQ:EDIT$1.60 -0.05 (-2.73%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Elevation Oncology NASDAQ:ELEV$0.35 -0.02 (-6.62%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Fate Therapeutics NASDAQ:FATE$1.24 -0.05 (-3.52%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Century Therapeutics NASDAQ:IPSC$0.55 +0.01 (+1.92%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Johnson & Johnson NYSE:JNJ$154.69 -1.62 (-1.04%) As of 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Y-mAbs Therapeutics NASDAQ:YMAB$4.10 -0.15 (-3.53%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
